Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Front Psychiatry
Although GLP-1s arent officially approved for this use, some longevity-focused doctors are prescribing them off-label as part of a broader prevention plan due to all the potential benefits
In this real-world setting, patients who were treated with semaglutide 2.4 mg and tirzepatide had a mean weight loss of 14.1% and 16.5% at 1 year, respectively, which represents a clinically meaningful weight loss with both therapies when used in patients with overweight or obesity and without T2DM [20]
This patient information is based on a leaflet from the Faculty of Sexual and Reproductive Healthcare (FSRH) and the Primary Care Womens Health Society
doi: 10.18502/jnfs.v10i1.17769 132
All participants were publicly insured
